细胞角蛋白20在51例膀胱尿路上皮癌中的表达

Expression of cytokeratin20 in 51 cases of bladder urothelial carcinoma

目的探讨细胞角蛋白20(CK20)在膀胱尿路上皮癌中的表达及其诊断应用价值。方法应用免疫组织化学技术检测51例膀胱尿路上皮癌和22例非肿瘤性膀胱黏膜中CK20的表达,并分析肿瘤细胞中CK20表达与膀胱尿路上皮癌临床病理特征的关系。结果CK20在膀胱尿路上皮癌中的阳性表达率为72.55%,在非肿瘤性膀胱黏膜中无表达(P<0.001)。CK20阳性表达与肿瘤组织学分级和肿瘤分期成正相关(P值均<0.05),而与患者性别、肿瘤的大小和数目不相关(P>0.05)。结论CK20可作为膀胱尿路上皮癌诊断的一个重要的免疫标记抗体,其检测为膀胱尿路上皮癌恶性程度的判定、预后分析及临床治疗提供了有效的依据。

Objective To appraise the expression of cytokeratin20(CK20) in bladder urothelial carcinoma and its value in pathological diagnosis. Methods Immunohistochemical staining for CK20 was performed in 51 cases of bladder urothelial carcinoma and 22 cases of non-neoplastic bladder mucosa.The expression of CK20 in tumor cells was correlated with the clinicopathological characteristics of bladder urothelial carcinoma.Results The positive rate of CK20 in bladder urothelial carcinoma was 72.55%, while no CK20 expression was found in non-neoplastic bladder mucosa(P<0.001). The positive expression of CK20 was significantly correlated with histological grading and tumor staging(P<0.05), but not related to the patients’ sex and the number or size of the tumor(P>0.05).Conclusion CK20 might be an important marker in the diagnosis of bladder urothelial carcinoma. Detection of CK20 can predict the degree of malignancy and prognosis, providing the theoretical basis for clinical treatment.